Prognosis of hepatocellular carcinoma: Comparison of 7 staging systems in an American cohort

Hepatology

Volumn 41, Issue 4, 2005, Pages 707-715

  Marrero, Jorge A ^a,b   Fontana, Robert J ^a   Barrat, Ashley ^a   Askari, Frederick ^a   Conjeevaram, Hari S ^a   Su, Grace L ^a   Lok, Anna S ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CANCER THERAPY; CATHETER ABLATION; CAUSE OF DEATH; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PORTAL VEIN THROMBOSIS; PRIORITY JOURNAL; PROGNOSIS; SCORING SYSTEM; TUMOR VOLUME;

EID: 16244369103     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.20636     Document Type: Article

References (39)

1. El-Serag HB. Hepatocellular carcinoma and hepatitis C in the United States. HEPATOLOGY 2002;36:S74-S83.
2. Howe HL, Wingo PA, Thun MJ, Ries LA, Rosenberg HM, Feigal EG, et al. Annual report to the nation on the status of cancer (1973 through 1998), featuring cancers with recent increasing trends. J Natl Cancer Inst 2001;93:824-842.
3. El-Serag HB, Mason AC, Key C. Trends in survival of patients with hepatocellular carcinoma between 1977 and 1996 in the United States. HEPATOLOGY 2001;33:62-65.
4. Tanaka Y, Hanada K, Mizokami M, Yeo AE, Shih JW, Gojobori T, et al. A comparison of the molecular clock of hepatitis C virus in the United States and Japan predicts that hepatocellular carcinoma incidence in the United States will increase over the next two decades. Proc Natl Acad Sci U S A 2002;99:15584-15589.
5. Compton CC, Fielding LP, Burgart LJ, Conley B, Cooper HS, Hamilton SR, et al. Prognostic factors in colorectal cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 2000;124:979-994.
6. Gleason DF, Veterans Administration Cooperative Urological Research Group. Histologic grading and staging of prostatic carcinoma. In: Tannenbaum M, ed. Urologic Pathology: The Prostate. Philadelphia: Lea & Febiger, 1977:171-187.
7. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL Conference. J Hepatol 2001;35:421-430.
8. Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999;19:329-338.
9. The Cancer of the Liver Italian Program (CLIP) Investigators. Prospective validation of the CLIP score: a new prognostic system for patients with cirrhosis and hepatocellular carcinoma. HEPATOLOGY 2000;31:840-845.
10. Leung TW, Tang AM, Zee B, Lau WY, Lai PB, Leung KL, et al. Construction of the Chinese University Prognostic Index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, and the Cancer of the Liver Italian Program staging system: a study based on 926 patients. Cancer 2002;94:1760-1769.
11. Kudo M, Chung H, Osaki Y. Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging score (JIS score). J Gastroenterol 2003;38:207-215.
12. Okuda K, Ohtsuki T, Obata H, Tomimatsu M, Okazaki N, Hasegawa H, et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer 1985;56:918-928.
13. Chevret S, Trinchet JC, Mathieu D, Rached AA, Beaugrand M, Chastang C, for the Groupe d'Etude et de Traitement du Carcinome Hépatocellulaire. A new prognostic classification for predicting survival in patients with hepatocellular carcinoma. J Hepatol 1999;31:133-141.
14. UNOS/OPTN policy 3.6.4.4. Available at http://www.optn.org. Accessed May 20, 2004.
15. Wildi S, Pestalozzi BC, McCormack L, Clavien PA. Critical evaluation of the different staging systems for hepatocellular carcinoma. Br J Surg 2004;91:400-408.
16. Marrero JA, Su GL, Wei W, Emick D, Conjeevaram HS, Fontana RJ, et al. Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from non-malignant chronic liver disease in American patients. HEPATOLOGY 2003;37:1114-1121.
17. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
18. Cox DR. Regression models and life tables. J R Stat Soc 1974;34:187-220.
19. Ueno S, Tanabe G, Sako K, Hiwaki T, Hokotate H, Fukukura Y, et al. Discrimination value of the new western prognostic system (CLIP score) for hepatocellular carcinoma in 662 Japanese patients. HEPATOLOGY 2001;34:529-534.
20. Hosmer DW, Hosmer T, Le Cessie S, Lemeshow S. A comparison of goodness-of-fit tests for the logistic regression model. Stat Med 1997;16:965-980.
21. Feinsten AR. Clinical biostatistics XVI. The process of prognostic stratification. Clin Pharmacol Ther 1972;13:609-624.
22. Foster MR. Key concepts in model selection: performance and generalizability. J Math Psychol 2000;44:205-231.
23. Parzen M, Lipsitz SR. A global goodness-of-fit statistic for Cox regression models. Biometrics 1999;55:580-584.
24. Llovet JM, Bustamante J, Castells A, Vilana R, Ayuso MC, Sala M, et al. Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. HEPATOLOGY 1999;29:62-67.
25. Buccheri G, Ferrigno D, Tamburini M. Karnofsky and ECOG performance status scoring in lung cancer: a prospective, longitudinal study of 536 patients from a single institution. Eur J Cancer 1996;32:1135-1141.
26. Wiesner R, Edwards E, Freeman R, Harper A, Kim R, Kamath P, et al. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology 2003;124:91-96.
27. Fong Y, Sun RL, Jarnagin W, Blumgart LH. An analysis of 412 cases of hepatocellular carcinoma at a Western center. Ann Surg 1999;229:790-799.
28. Poon RT, Fan ST, Lo CM, Liu CL, Wong J. Intrahepatic recurrence after curative resection of hepatocellular carcinoma: long-term results of treatment and prognostic factors. Ann Surg 1999;229:216-222.
29. Shetty K, Timmins K, Brensinger C, Furth EE, Rattan S, Sun W, et al. Liver transplantation for hepatocellular carcinoma validation of present selection criteria in predicting outcome. Liver Transpl 2004;10:911-918.
30. Jiang ZB, Shan H, Shen XY, Huang MS, Li ZR, Zhu KS, et al. Transjugular intrahepatic portosystemic shunt for palliative treatment of portal hypertension secondary to portal vein tumor thrombosis. World J Gastroenterol 2004;10:1881-1884.
31. Schoniger-Hekele M, Muller C, Kutilek M, Oesterreicher C, Ferenci P, Gangl A. Hepatocellular carcinoma in central Europe: prognostic features and survival. Gut 2001;48:103-109.
32. Calvet X, Bruix J, Gines P, Bru C, Sole M, Vilana R, et al. Prognostic factors of hepatocellular carcinoma in the west: a multivariate analysis in 206 patients. HEPATOLOGY 1990;12:753-760.
33. Cillo U, Bassanellos M, Vitale A, Grigoletto FA, Burra P, Fagiuoli S, et al. The critical issue of hepatocellular carcinoma prognostic classification: which is the best tool available? J Hepatol 2004;40:124-131.
34. Levy I, Sherman M. Staging of hepatocellular carcinoma: assessment of the CLIP, Okuda and Child-Pugh staging systems in a cohort of 257 patients in Toronto. Gut 2002;50:881-885.
35. Farinati F, Rinaldi M, Gianni S, Naccarato R. How should patients with hepatocellular carcinoma be staged? Validation of a new prognostic system. Cancer 2000;89:2266-2273.
36. Henderson JM, Sherman M, Tavill A, Abecassis M, Chejfec G, Gramlich T. AHPBA/AJCC consensus conference on staging of hepatocellular carcinoma: consensus statement. HPB Surg 2003;5:243-250.
37. Giannini E, Risso D, Botta F, Romagnoli P, Malfatti F, Fumagalli A, et al. Prognosis of hepatocellular carcinoma in anti-HCV positive cirrhotic patients: a single-centre comparison amongst four different staging systems. J Intern Med 2004;255:399-408.
38. El-Serag HB. Epidemiology of hepatocellular carcinoma. Clin Liver Dis 2001;5:87-107.
39. Sarbah SA, Gramlich T, Younoszai A, Osmack P, Goormastic M, Grosso L, et al. Risk factors for hepatocellular carcinoma in patients with cirrhosis. Dig Dis Sci 2004;49:850-853.